{"prompt": "['SPIMM-301 Version 4.0', '15 June 2018', 'APPENDIX 1. PART 1 SCHEDULE OF ASSESSMENTS', 'Period', 'Screening', 'Treatment Period', 'Follow-Up', 'Period', 'Period', 'Visit 1', 'Visit 2', 'Visit 3', 'Visit 4', 'Visit 5', 'Visit 6A', 'Visit', '(Screening)', '(Baseline/Day 1)c', '(Week 4)', '(Week 12)', '(Week 24)', '(End-of-Trial', 'or Early DC)', 'Window', '-28 Day to -1', 'Day 1', 'Day 29 2', 'Day 85 4', 'Day 169 + 14', 'Day 197 +14', 'Informed Consentd', 'X', 'Demographics', 'X', 'Review Inclusion/Exclusion Criteria', 'X', 'X', 'Review PART 2 Continuation Criteria', 'X', 'Medical/Surgical History\"', 'X', 'X (update)', 'Concomitant Medication/Procedure Review', 'X', 'X (update)', 'X', 'X', 'X', 'X', 'Review AEs/ADEs', 'X', 'X', 'X', 'X', 'X', 'X', 'Physical Examination', 'X', 'X', 'X', 'X', 'X', 'X', 'Vital Signs', 'X', 'X', 'X', 'X', 'X', 'X', '12-Lead ECGg', 'X', 'X', 'X', 'X', 'X', 'X', 'C-SSRS \"Baseline/Screening\"', 'X', 'C-SSRS \"Since Last Visit\"', 'X', 'X', 'X', 'X', 'X', 'Clinical chemistry and hematology', 'X', 'X', 'X', 'X', 'X', 'X', 'laboratory parameters', 'Clinical Urinalysish', 'X', 'X', 'X', 'X', 'X', 'X', 'Pregnancy Test\u00b9', 'X', 'X', 'X', 'PK Samples\u00b9', 'X', 'X', 'X', 'PMMSA', 'X\u00b0', 'Daily', 'X', 'Neuro-QoL Fatigue', 'X', 'X', 'X', 'X', 'X', 'EQ-5D-5L', 'X', 'X', 'X', 'X', 'X', 'PGI Scales', 'X', 'X', 'X', 'X', 'X', 'CGI Scales', 'X', 'X', 'X', 'X', 'X', '6MWTk', 'X', 'X', 'X', 'X', 'X', 'IMP Administration\u00b9', 'X', 'Daily', 'X', 'ISR Assessment', 'X', 'X', 'X', 'X', 'a.', \"Screening will begin with the subject's signature of the informed consent form (ICF) and will last a minimum of 7 days to a maximum of 28\", 'days.', 'Subjects', 'not previously enrolled in SPIMM-300, however, may have a longer screening period for review by the Adjudication Committee to determine', 'their', 'eligibility for study enrollment.', 'b. All clinical site visits should occur at approximately (2 hours) the same time during the day and subjects should have at least 1 hour of fasting (e.g. no large', 'meals) prior to the 6MWT. Trial Days are relative to the Baseline Visit (Day 1).', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '82']['SPIMM-301 Version 4.0', '15 June 2018', 'c.', 'Baseline assessments must be completed within 24 hours prior to receiving IMP.', 'd.', 'The ICF must be signed prior to any trial-related procedures are performed.', 'e. Height will only be measured at the Screening Visit, and used in the trial to calculate BMI. Physical examination will include: general appearance, skin,', 'head, eyes, ears, nose, throat, neck (including thyroid), lymph nodes, chest, heart, abdomen, extremities, nervous system, and weight.', 'f.', 'Vital signs will include HR, RR, and BP after sitting for 5 min, and temperature.', 'g. All scheduled ECGs must be performed after the subject has rested quietly for at least 5 min in the supine position.', 'h.', 'Blood samples will be collected prior to the IMP administration on the Baseline Visit. Analysis will include testing for parameters included in Appendix 4.', 'Additional blood samples at the Baseline, Week 24 Visit, and Early Discontinuation Visit (if applicable) will be collected and stored for assessing the', 'immunogenicity potential of the IMP.', 'i.', 'Serum pregnancy test will be done for women of childbearing potential at the Screening Visit. Results of the Baseline Visit pre-dose urine pregnancy test', 'must be evaluated before randomization to ensure eligibility. Urine pregnancy test will also be performed for women of childbearing potential at the End-of-', 'Trial/Early Discontinuation Visit.', 'j.', 'PK', 'Schedule: Week 4: 1 hour post dose ( 10 min); Week 12: 30 min, 2 hours, and 4 hours post dose ( 10 min); Week 24: pre-dose (-10 min).', 'k. The 6MWT should be performed after all other trial procedures (except for PMMSA at the Screening Visit and the IMP administration at the Baseline Visit).', 'The 6MWT instructions are provided in Appendix 13.', '1.', 'Subjects', '(and caregivers if needed) will be trained on the procedure for administration of the elamipretide delivery system (the investigational medicinal', 'product [IMP] [elamipretide or placebo], the elamipretide pen injector, and needle). On days of trial visits, the IMP administered with the elamipretide', 'delivery system should be administered at the clinical site. At Baseline Visit, the IMP administration will occur after the completion of all Visit procedures.', 'At the Week 4, Week 12, and Week 24 Visits, the IMP administration should occur after all other trial procedures. The location (injection in the', 'abdomen,', 'rotating around the four abdominal quadrants, or other appropriate location [after Investigator consultation with the Sponsor]) and time (at approximately the', 'same time each day [e.g., early morning, noon, or early afternoon]) of the IMP administration will be recorded daily in a diary. Supplies will be collected,', 'compliance will be assessed, and new supplies will be provided at clinical site visits. For subjects continuing into PART 2 of the trial, IMP administration', 'the day of the Week 24 Visit will use the PART 2 supply of IMP. Subjects not continuing into PART 2 will not be administered IMP at the Week 24 Visit.', 'm.', 'The skin examination should occur at 30 (+5) minutes after the IMP administration with the elamipretide delivery system. The presence and severity of fapin,', 'erythema, swelling, and pruritus at the injection site will be assessed. Scoring of erythema, swelling, pruritus and pain will be done using a 5-point scale', 'using the \"Table for Grading the Severity of Site Reactions to Injections\" provided in Appendix 14.', 'n.', 'Obtain previous genetic testing results from subjects not previously enrolled in SPIMM-300.', 'o.', 'The PMMSA at the Screening Visit should be the last trial assessment completed.', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '83']\n\n###\n\n", "completion": "END"}